Medical News / ESC 2022 - SGLT2 Inhibitor Therapy Foundational in Wide Range of Heart Failure Management

SGLT2 inhibitors reduce the risk of hospitalization for heart failure, extend survival, and improve overall health status, irrespective of ejection fraction, in patients with heart failure. Source: MDMag To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

read more

On-demand treatment with vonoprazan completely resolved heartburn in less than 3 hours with sustained relief for ... read more
Once-weekly 2.4 mg semaglutide is associated with an approximate 60% reduced risk of type 2 diabetes in patients ... read more
Although the potential effects of global warming on human health continue to concern experts, the impact ... read more
Fish oil supplement intake may increase the long-term risk of atrial fibrillation (AF) in a healthy ... read more